GC Cell announced on Tuesday that it has filed a patent for immunotherapy targeting solid tumors.
This patent, based on GC Cell’s Chimeric Antigen Receptor Natural Killer (CAR-NK) platform, represents a pipeline developed with Claudin 18.2 as the Target, expanding its potential applications in the solid tumor field.
Claudin 18.2, a protein expressed in various solid tumors including gastric, pancreatic, and esophageal cancers, has recently caught the attention of the global pharmaceutical and biotech industries as a key therapeutic Target.
Unlike Chimeric Antigen Receptor T-cell (CAR-T) therapies that use a patient’s own cells, CAR-NK therapies utilize cells from healthy donors. This approach allows for mass production of a universal treatment, offering a significant advantage.
The therapy is expected to provide high safety due to the innate immune properties of NK cells. It’s also seen as a promising alternative that could reduce treatment costs and improve patient access through more efficient manufacturing and supply processes.
Won Sung-yong, Chief Executive Officer (CEO) of GC Cell, stated that this patent is another milestone in the ongoing research and development of the CAR-NK platform-based solid tumor pipeline. He added that it will continue to strengthen the global competitiveness through further research and development in this area.